Ionis Pharmaceuticals, Inc. Tech Stack

RNA-targeted medicine developer with five marketed drugs and clinical-stage pipeline

Biotechnology Research Carlsbad, CA 501–1,000 employees Founded 1989 Public Company

Ionis is a public biotech company commercializing RNA-targeted therapeutics across neurology, cardiology, and other indications. The tech stack reveals a pharma-ops-heavy footprint—SAP, Veeva, Coopa, Databricks—alongside life-science tools (LC-MS, RNA-seq, qPCR, ChIP-seq). Hiring velocity is accelerating across research, sales, and operations, with director-level roles dominating; the active project list shows concurrent work on first commercial product launch, targeted delivery mechanisms, and safety/compliance infrastructure, indicating a company scaling from pipeline to revenue while managing the regulatory complexity of marketed medicines.

Tech Stack 18 technologies

Core StackPython AWS SAP SAP S/4HANA Smartsheet Okta Databricks Power Platform Power Automate LC-MS AWS CDK Veeva Coupa qPCR ChIP-seq RNA-seq Azure OneDrive

What Ionis Pharmaceuticals, Inc. Is Building

◆Challenges

Launching new product
Optimal patient access
Identifying novel therapeutic targets for heart failure
Delivery challenges
Building local healthcare relationships
Expedited reporting compliance
Vendor compliance management
Targeted delivery of nucleic acid therapeutics
Optimizing vendor portfolio
Ensuring timely product release

▲Active Projects

Supply strategy development
Launch of ionis’s first wholly owned commercial product
Launching first commercial product
Targeted rna-therapeutics delivery to immune cells
Signal detection activities
Aggregating and harmonizing proteomic and eeg datasets
Drug safety surveillance support
Safety database administration
Inspection readiness
Oligonucleotide conjugate development for targeted delivery

Hiring Activity

Accelerating45 roles · 25 in 30d

Department

Research

Sales

Ops

Healthcare

Data

Legal

Manufacturing

Engineering

Seniority

Director

Mid

Senior

Principal

Notable leadership hires: Executive Director, Associate Director

Company intelligence

Find more companies like Ionis Pharmaceuticals, Inc. by tech stack, pain points and active projects

Get started free

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals is a public biotechnology company headquartered in Carlsbad, California, focused on RNA-targeted medicines. The company has five marketed medicines currently in use and maintains a clinical pipeline in neurology, cardiology, and other therapeutic areas. Founded in 1989, Ionis pioneered RNA-targeted drug development and continues to advance both RNA therapeutics and gene-editing approaches. The organization operates across research, commercial sales, manufacturing, data analytics, healthcare, legal, and regulatory functions, with active hiring in the United States and India. Core challenges center on commercial product launch execution, patient access optimization, and delivery mechanisms for nucleic acid therapeutics.

HeadquartersCarlsbad, CA

Company Size501–1,000 employees

Founded1989

Hiring MarketsUnited States, India

Frequently Asked Questions

What is Ionis Pharmaceuticals' technology platform?

Ionis specializes in RNA-targeted medicines—the pioneer in this therapeutic class. The platform extends to gene editing and targeted delivery of nucleic acid therapeutics, particularly to immune cells and other tissues.

How many marketed drugs does Ionis have?

Ionis currently has five marketed medicines available to patients, with an additional pipeline of clinical-stage candidates in neurology, cardiology, and other disease areas.

How this profile is built

Ionis Pharmaceuticals, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →

This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.